Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.prnewswire.com/news-releases/results-of-novel-clinical-study-of-guselkumab-and-golimumab-combination-therapy-show-adults-with-moderately-to-severely-active-ulcerative-colitis-maintained-higher-rates-of-clinical-histologic-and-endoscopic-remission-at-week-38-301644127.html
0
0
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38 - PR Newswire
10/10/22 at 10:30am
Organization
PRNewswire
Authors
Details
56 words
Summarize
Health
Novel Clinical Study of Guselkumab
Golimumab Combination Therapy Show
Histologic
Endoscopic Remission
PRNewswire
Phase 2a
Janssen Pharmaceutical Companies of Johnson & Johnson
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing...
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...